Cipla Primes Biosimilars Play Via South African Beachhead

South Africa’s first biotech manufacturing facility is being set up by India's Cipla which hopes its strategy of "one global product standard at affordable pricing" could transform the biosimilars market. Some years ago, Cipla revolutionized treatment for HIV/AIDS with its less than a dollar a day treatment, though some analysts claim that it's still very early days to factor any disruptive impact that the firm could potentially have in the complex biosimilars segment.